History

Advanced Accelerator Applications (AAA), was founded in 2002, by physicist Stefano Buono, with the goal of commercializing a patent developed during his tenure at the European Organization for Nuclear Research, or CERN, with Nobel laureate Carlo Rubbia.

2002

Stefano Buono founded AAA as a “spin-off” of the European Organization for Nuclear Research (CERN).

2002

Built first radiopharmaceutical laboratory in the Technoparc of Saint-Genis-Pouilly (France).

2004

Achieved first Marketing Authorization to commercialize GLUSCAN® in Switzerland.

2006

Completed construction of second radiopharmaceutical production plant in Venafro (Molise, Italy).

2007

Completed construction of third radiopharmaceutical production plant in the Silvano Fumero Bioindustry park in Ivrea (Piedmont, Italy).

2008

Completed construction of fourth radiopharmaceutical production plant in Troyes (France) to produce GLUSCAN® and PET Investigational Medical Products (IMP).

2008

Completed construction of fifth radiopharmaceutical production plant in Béthune (France) to produce GLUSCAN® and PET Investigational Medical Products (IMP).

2008

Signed exclusive license agreement with Bracco Diagnostics Inc. for distribution of CARDIOGEN-82® (Rb-82 generator for Cardiac PET) in Europe.

2009

Completed acquisition of Gipharma, an Italian pharmaceutical contract manufacturer for injectable and freeze-dried products.

2009

Started construction of two radiopharmaceutical production plants in Meldola (Forlì, Italy) and in “La Almunia de Doña Godina” (Zaragoza, Spain).

2009

Signed exclusive license agreement with IASON for manufacture and distribution of F18 PET diagnostic products.

2010

Made initial investment in Atreus Pharmaceuticals Corporation, a Canadian biopharmaceutical company headquartered in Ottawa.

2010

Acquired BioSynthema Inc., a U.S. molecular nuclear medicine discovery company based in St. Louis, Missouri to obtain the rights to develop and commercialize LUTATHERA® (lutetium Lu 177 dotatate).

2011

Raised €40 million from existing and new investors to advance and grow pipeline and expand PET manufacturing network.

2011

Acquired FabOvar, a humanized monoclonal antibody fragment from Dompé.

2011

Established third-party manufacturing agreement with GE Healthcare.

2012

Initiated global Phase 3 study of LUTATHERA® (lutetium Lu 177 dotatate).

2012

Established direct presence in Germany with acquisition of majority stake in Umbra medical AG, a German radiopharmaceutical company.

2012

AAA celebrates 10-year anniversary.

2012

Acquired fully operational PET production laboratory in Porto, Portugal.

2013

Strengthened position in Spain with acquisition of two radiopharmaceutical companies, Barnatron and Catalana De Dispensación, S.A. (Cadisa).

2013

Signed new third-party PET manufacturing agreements with Eli Lilly and GE Healthcare.

2013

Entered Polish market following agreement with University of Warsaw.

2013

Completed construction of new global headquarters in Saint-Genis-Pouilly, France.

2014

Raised €41 million to accelerate international expansion, including an increased presence in the U.S., and to support clinical trials.

2014

Received orphan drug designation from FDA and EMA for NETSPOT® gallium Ga 68 dotatate.

2014

Entered UK and Irish nuclear medicine markets with the acquisition of Imaging Equipment Ltd. (IEL).

2014

Established U.S. subsidiary with an office in New York City.

2014

Started commercial operations in 3 new production sites: Warsaw, Bonn, Marseille.

2015

Raised €23 million in a crossover financing with U.S.-based healthcare institutions.

2015

Announced Phase 3 NETTER-1 study evaluating LUTATHERA® (lutetium Lu 177 dotatate).

2015

Completed $125 million Initial Public Offering and listed on the Nasdaq Global Select Market under the ticker “AAAP”.

2016

Acquired IDB Group in The Netherlands, securing supply of lutetium 177 (Lu-177) for LUTATHERA® (lutetium Lu 177 dotatate)  and future therapeutic candidates.

2016

Signed exclusive license with Johns Hopkins University for PSMA receptor ligands for prostate cancer.

2016

Opened Expanded Access Program in the U.S. for LUTATHERA® (lutetium Lu 177 dotatate).

2016

Expanded presence in Germany with acquisition of two production sites in Erlangen and Munich.

2016

FDA approved NETSPOT® (gallium Ga 68 dotatate) for PET imaging.

2016

Expanded theragnostic pipeline with NeoB, targeting GRPR receptor expressed in multiple solid tumors.

 

2016

Established first U.S. distribution and manufacturing site in Millburn, New Jersey.

2016

Raised $172.2 million from U.S.-based institutions to support ongoing operations.

2016

European Commission approved SomaKit TOC® (gallium (Ga 68) edotreotide) for PET imaging.

New England Journal of Medicine Logo
2017

Results of Phase 3 NETTER-1 study published in New England Journal of Medicine.

2017

AAA celebrates 15-year anniversary.

2017

CHMP Opinion Recommending Approval of LUTATHERA® (lutetium 177Lu oxodotreotide).

2017

First clinical study with LUTATHERA® (lutetium Lu 177 dotatate) started in Japan.

2017

European approval of LUTATHERA® (lutetium 177Lu oxodotreotide).

Novartis
2018

AAA acquired by Novartis.

2018

FDA approval of LUTATHERA® (lutetium Lu 177 dotatate).

2018

Signed exclusive license agreement with Cancer Targeted Technology (CTT) to develop CTT1057.

2018

First clinical studies with PSMA-R2.

2018

First clinical studies with NeoB.

2018

Signed exclusive license agreement with FUJIFILM Toyama Chemical Co,. LTD to develop and commercialize radiolabeled FF-10158 for oncology indications.

Endocyte Vision logo
2018

Novartis successfully completes acquisition of Endocyte, Inc.

2019

Health Canada Approval of LUTATHERA (lutetium 177Lu oxodotreotide).

2019

European approval of LysaKare® for reduction of kidney exposure to radiation during PRRT with LUTATHERA® (lutetium 177Lu oxodotreotide).

2019

State of Israel Ministry of Health Approval for Lutathera® (lutetium 177Lu oxodotreotide).

2019

Swissmedic approval for LUTATHERA® (lutetium 177Lu oxodotreotide).